Description
Glecaprevir (ABT 493; A 1282576) is a novel HCV NS3/4A protease inhibitor with pan-genotypic activity, inhibits NS3/4A proteases from HCV genotypes 1-6 in vitro with IC50 of 3.5-11.3nM; inhibits the replication of stable HCV subgenomic replicons genotypes 1-6 with EC50 of 0.21-4.6nM, has a median EC50 of 0.30nM (0.05 - 3.8nM) for HCV replicons containing proteases from 40 HCV genotype 1-5 samples; the combination of ABT-493 and ABT-530 demonstrates potent antiviral activity and acceptable safety in clinical trails with HCV genotype 1 infection. HCV Infection Phase 2 Clinical